Registered title, quoted from ClinicalTrials.gov
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06888648, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pancreatic ductal adenocarcinoma (PDAC) diagnosed by pathology (histology or cytology);
Inclusion criterion 13
Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age included premenopause and women within 2 years after menopause;
Inclusion criterion 9
Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age include premenopause and women within 2 years after menopause;
Inclusion criterion 17
An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;
Inclusion criterion 5
An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;
Inclusion criterion 15
According to the efficacy evaluation criteria for solid tumors (RECIST 1.1);
Inclusion criterion 6
At the same time with other malignant tumors, but cured basal cell cancer, thyroid cancer, cervical dysplasia, etc., have been in the disease for more than 5 years or do not considered to be easy to relapse except;
Exclusion criterion 2
Patients with positive human immunodeficiency virus (HIV) antibody, positive treponema pallidum for syphilis (TP) antibody, active hepatitis C (positive hepatitis C virus (HCV) antibody and positive HCV RNA result), active hepatitis B;
Exclusion criterion 6
Women born during pregnancy or lactation;
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06888648, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
(1) Subjects who meet all the following entry criteria enter the pre-screening phase of the study:
- Voluntary signing of the informed consent form;
- Age: 18 and 75 years old, male or female;
- Evaluation as metastatic pancreatic cancer or postoperative recurrence according to the 2024 NCCN guidelines;
- No systemic treatment, or disease progression with gemcitabine-based first-line chemotherapy.
- An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;
- According to the efficacy evaluation criteria for solid tumors (RECIST 1.1);
- Can obtain sufficient fresh tumor tissue samples for exome and transcriptome sequencing analysis;
- Main organ function of heart, liver and kidney is normal:
- Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age included premenopause and women within 2 years after menopause;
- Ability to follow the study protocol and follow-up procedures.
(2) Subjects who meet all the following enrollment criteria enter the formal screening stage of the study and enter the study medication process:
- Voluntary signing of the informed consent form;
- Age: 18 and 75 years old, male or female;
- Pancreatic ductal adenocarcinoma (PDAC) diagnosed by pathology (histology or cytology);
- No systemic treatment or gemcitabine-based first-line chemotherapy.
- An Eastern Cooperative Oncology Group (ECOG) physical fitness status score of 0 or 1;
- Main organ function of heart, liver and kidney is normal:
- Ferproductive men and women of childbearing age agree to take effective contraception from the date to the last dose of test drug; women of childbearing age include premenopause and women within 2 years after menopause;
- Ability to follow the study protocol and follow-up procedures.
Exclusion Criteria:
Subjects will be excluded from this study if they meet any of the following criteria:
- Pancreatic cancer has central nervous system metastasis or meningeal metastasis;
- At the same time with other malignant tumors, but cured basal cell cancer, thyroid cancer, cervical dysplasia, etc., have been in the disease for more than 5 years or do not considered to be easy to relapse except;
- History of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation;
- Patients with immunosuppressants, that is, those who require regular use of immunosuppressants 4 weeks before the screening period and the clinical study, including but not limited to the following conditions: severe asthma, autoimmune diseases or immune deficiency, treated with immunosuppressive drugs, and known history of primary immunodeficiency; except type 1 diabetes, autoimmune-related hypothyroidism requiring hormone therapy, vitiligo and psoriasis that do not require systemic therapy;
- Active bacterial or fungal infection identified by clinical diagnosis; a history of active TB or tuberculosis;
- Patients with positive human immunodeficiency virus (HIV) antibody, positive treponema pallidum for syphilis (TP) antibody, active hepatitis C (positive hepatitis C virus (HCV) antibody and positive HCV RNA result), active hepatitis B;
- Herpesvirus infection (except those who scab for more than 4 weeks); respiratory virus infection (except those who have recovered for more than 4 weeks);
- Uncontrolled complications include but are not limited to active infection, symptomatic congestive heart failure, unstable angina, arrhythmia; severe coronary artery disease or cerebrovascular disease, or other diseases considered unacceptable by the investigator;
- Previous history of drug abuse, clinical or psychological or social factors affecting informed consent or study implementation; a history of mental illness;
- Patients with a history of food, drug or vaccine allergy or other potential immunotherapy allergies as considered by the Investigator.
- Women born during pregnancy or lactation;
- The investigator is not fit for enrollment or may not complete the trial for other reasons.
Quoted from ClinicalTrials.gov, NCT06888648, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06888648, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.